摘要
目的：探讨喹硫平与舒必利治疗以阴性症状为主的精神分裂症患者的临床疗效及安全性。方法将106例以阴性症状为主的精神分裂症患者随机分为两组，分别口服喹硫平、舒必利治疗，比较两组的临床疗效及不良反应。结果喹硫平组总有效率为88．7％，舒必利组为62．3％，喹硫平组显著高于舒必利组（ P＜0．01）。喹硫平组副反应量表的行为、神经系统、植物神经系统不良反应评分均显著低于舒必利组（P＜0．01）。结论喹硫平治疗以阴性症状为主的精神分裂症临床疗效显著优于舒必利，能有效改善患者的阴性症状，安全性高，值得在临床推广应用。
Objective To explore the efficacy and safety of quetiapine and sulpiride in schizophrenia charac‐terized by negative symptoms .Methods A total of 106 schizophrenics characterized by negative symptoms were randomly assigned to two groups taking orally quetiapine or sulpiride .Efficacy and adverse reactions were compared between two groups .Results The total effective rate was significantly higher in quetiapine than sulpiride group （88 .7% vs 62 .3% , P〈0 .01） .Scores no behaviors ,nervous system and vegetative nervous system adverse reactions were significantly lower in quetiapine than sulpiride group （P〈0 .01） . Conclusion Quetiapine has a more evident effect than sulpiride does in schizophrenia characterized by neg‐ative symptoms ,could effectively improve patients’ negative symptoms ,and has higher safety .
出处
《临床心身疾病杂志》
CAS
2015年第1期134-135,共2页
Journal of Clinical Psychosomatic Diseases
